The TB pandemic: An old problem seeking new solutions

Journal of Internal Medicine

Volumn 261, Issue 4, 2007, Pages 309-329

  Meya, D B ^a,b   McAdam, K P W J ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b Infectious Diseases Institute   (Uganda)

Author keywords

Diagnosis; Drug resistance; HIV; Treatment; Tuberculosis; Vaccines

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; BCG VACCINE; CLOFAZIMINE; CYCLOSERINE; DAPSONE; DNA VACCINE; ETHAMBUTOL; ETHIONAMIDE; EUROCINE; IMMUNOLOGICAL ADJUVANT; INFLIXIMAB; ISONIAZID; LIVE VACCINE; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM MICROTI VACCINE; MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85A; MYCOBACTERIUM VACCAE VACCINE; MYCOBACTERIUM VACCINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACID FAST BACTERIUM; BACTERIUM CULTURE; CELLULAR IMMUNITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE COURSE; DRUG INTERMITTENT THERAPY; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE MICROSCOPY; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFECTION CONTROL; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOUTH AFRICA; STAINING; SUPERINFECTION; TH2 CELL; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; DISEASE OUTBREAKS; HUMANS; RISK FACTORS; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH;

EID: 33947511253     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01795.x     Document Type: Review

References (166)

1. Dormandy T. The White Death - A History of Tuberculosis. London: Hambledon Press, 1999.
2. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-6.
3. Furin JJ, Johnson JL. Recent advances in the diagnosis and management of tuberculosis. Curr Opin Pulm Med 2005; 11: 189-94.
4. de Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med 2004; 55: 283-301.
5. Human Development Report 2005 (lead author: Kevin Watkins). International Cooperation at a Crossroads: Aid, trade and security in an unequal world. United Nations Development Programme. 2005 p. 249.
6. Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
7. Odhiambo JA, Borgdoff MW, Kiambih FM. Tuberculosis and the HIV epidemic: increasing annual risk of infection in Kenya 1986-1996. Am J Public Health 1999; 89: 1078-82.
8. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004; 42: 2379-87.
9. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-37.
10. Leroy V, Salmi LR, Dupon M et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease. Am J Epidemiol 1997; 145: 293-300.
11. Whalen C, Horsburg CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.
12. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-12.
13. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa. Lancet 2002; 359: 2059-64.
14. Lederberger B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV cohorts study. JAMA 1999; 282: 2220-6.
15. Jones JL, Hanson MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuber Lung Dis 2000; 4: 1026-31.
16. Levin M, Newport M. Inherited predisposition to mycobacterial infection: historical considerations. Microbes Infect 2000; 2: 1549-52.
17. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev 2001; 23: 288-301.
18. Grzybowski S, Barnett GD, Stylbo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 5: 90-106.
19. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954; 69: 724-32.
20. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84: 29-44.
21. Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 2005; 5: 661-7.
22. Lienhardt C, Fielding K, Sillah J et al. Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med 2003; 168: 448-55.
23. Accorsi S, Fabiani M, Nattabi B et al. The disease profile of poverty: morbidity and mortality in northern Uganda in the context of war, population displacement and HIV/AIDS. Trans R Soc Trop Med Hyg 2005; 99: 226-33.
24. Cantwell MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998; 157: 1016-20.
25. Pai M, Gokhale K, Joshi R et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005; 293: 2746-55.
26. Kayanja HK, Debanne S, King C, Whalen CC. Tuberculosis infection among health care workers in Kampala, Uganda. Int J Tuberc Lung Dis 2005; 9: 686-8.
27. Markowitz SB. Epidemiology of tuberculosis among health care workers. Occup Med 1994; 9: 589-608.
28. Lienhardt C, Fielding K, Sillah JS et al. Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. Int J Epidemiol 2005; 34: 914-23.
29. Marquet S, Schurr E. Genetics of susceptibility to infectious diseases: tuberculosis and leprosy as examples. Drug Metab Dispos 2001; 29: 479-83.
30. Fitness J, Floyd S, Warndorff DK et al. Large-scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern Malawi. Am J Trop Med Hyg 2004; 71: 341-9.
31. Bornman L, Campbell SJ, Fielding K et al. Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. J Infect Dis 2004; 190: 1631-41.
32. Bellamy R, Ruwende C, Corrah T et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 1999; 179: 721-4.
33. Wilkinson RJ, Llewelyn M, Toossi Z et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355: 618-21.
34. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 338: 640-44.
35. Li HT, Zhang TT, Zhou YQ, Huang QH, Huang J. SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis 2006; 10: 3-12.
36. Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, Newport MJ. Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1) and susceptibility to tuberculosis. J Infect Dis 2002; 186: 1808-14.
37. Liu W, Cao WC, Zhang CY et al. VDR and NRAMP1 gene polymorphisms in susceptibility to pulmonary tuberculosis among the Chinese Han population: a case-control study. Int J Tuberc Lung Dis 2004; 8: 428-34.
38. Lopez-Maderuelo D, Arnalich F, Serantes R et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167: 970-5.
39. Selvaraj P, Narayanan PR, Reetha AM. Association of functional mutant homozygotes of the mannose binding protein gene with susceptibility to pulmonary tuberculosis in India. Tuber Lung Dis 1999; 79: 221-7.
40. El Sahly HM, Reich RA, Dou SJ, Musser JM, Graviss EA. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis 2004; 36: 106-8.
41. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Assessment of the interleukin 1 gene cluster and other candidate gene polymorphisms in host susceptibility to tuberculosis. Tuber Lung Dis 1998; 79: 83-9.
42. Wilkinson RJ, Patel P, Llewelyn M et al. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 1999; 189: 1863-74.
43. Ogus AC, Yoldas B, Ozdemir T et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219-23.
44. Ben-Ali M, Barbouche MR, Bousnina S, Chabbou A, Dellagi K. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients. Clin Diagn Lab Immunol 2004; 11: 625-6.
45. Amirzargar AA, Yalda A, Hajabolbaghi M et al. The association of HLA-DRB, DQA1, DQB1 alleles and haplotype frequency in Iranian patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1017-21.
46. Brahmajothi V, Pitchappan RM, Kakkanaiah VN et al. Association of pulmonary tuberculosis and HLA in south India. Tubercle 1991; 72: 123-32.
47. Goldfeld AE, Delgado JC, Thim S et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA 1998; 279: 226-8.
48. Delgado JC, Baena A, Thim S, Goldfeld AE. Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis 2002; 186: 1463-8.
49. Akahoshi M, Nakashima H, Miyake K et al. Influence of interleukin-12 receptor beta1 polymorphisms on tuberculosis. Hum Genet 2003; 112: 237-43.
50. Tso HW, Lau YL, Tam CM, Wong HS, Chiang AK. Associations between IL12B polymorphisms and tuberculosis in the Hong Kong Chinese population. J Infect Dis 2004; 190: 913-9.
51. Dupuis S, Dargemont C, Fieschi C et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293: 300-3.
52. Dupuis S, Jouanguy E, Al-Hajjar S et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33: 388-91.
53. Caragol I, Raspall M, Fieschi C et al. Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency. Clin Infect Dis 2003; 37: 302-6.
54. Fieschi C, Dupuis S, Catherinot E et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med 2003; 197: 527-35.
55. Altare F, Durandy A, Lammas D et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280: 1432-5.
56. Tosh K, Campbell SJ, Fielding K et al. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci U S A 2006; 103: 10364-8.
57. Kaufmann SH, Cole ST, Mizrahi V, Rubin E, Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med 2005; 201: 1693-7.
58. Rajalingam R, Singal DP, Mehra NK. Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis. Tissue Antigens 1997; 49: 168-72.
59. Li CM, Campbell SJ, Kumararatne DS et al. Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. J Infect Dis 2002; 186: 1458-62.
60. Bellamy R, Beyers N, McAdam KP et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci U S A 2000; 97: 8005-9.
61. Cervino AC, Lakiss S, Sow O et al. Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families. Hum Mol Genet 2002; 11: 1599-603.
62. Bikmaeva AR, Sibiriak SV, Khusnutdinova EK. Insertional polymorphism of the CYP2E1 gene in infiltrative pulmonary tuberculosis in populations of Bashkortostan Republic. Mol Biol (Mosk) 2004; 38: 239-43.
63. Pan H, Yan BS, Rojas M et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005; 434: 767-72.
64. Ma X, Reich RA, Wright JA et al.. Association between interleukin-8 gene alleles and human susceptibility to tuberculosis disease. J Infect Dis 2003; 188: 349-55.
65. Cooke GS, Campbell SJ, Fielding K et al. Interleukin-8 polymorphism is not associated with pulmonary tuberculosis in the Gambia. J Infect Dis 2004; 189: 1545-6.
66. Newport MJ, Awomoyi AA, Blackwell JM. Polymorphism in the interferon-gamma receptor-1 gene and susceptibility to pulmonary tuberculosis in The Gambia. Scand J Immunol 2003; 58: 383-5.
67. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-91.
68. Corper HJ, Cohn ML. The viability and virulence of old cultures of tubercle bacilli; studies on 30-year-old broth cultures maintained at 37 degrees C. Tubercle 1951; 32: 232-7.
69. East African/British Medical Research Council. Second East African/British Medical Research Council Study. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second Report. Am Rev Respir Dis 1976; 114: 471-5.
70. Starke JR. Tuberculosis. An old disease but a new threat to the mother, fetus, and neonate. Clin Perinatol 1997; 24: 107-27.
71. Walker L, Lowrie DB. Killing of Mycobacterium microti by immunologically activated macrophages. Nature 1981; 293: 69-71.
72. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005; 74: 35-9.
73. Vlachaki E, Psathakis K, Tsintiris K, Iliopoulos A. Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med 2005; 99: 648-52.
74. Marchant A, Amedei A, Azzurri A et al. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. Am J Respir Cell Mol Biol 2001; 24: 187-94.
75. Surcel HM, Troye-Blomberg M, Paulie S et al.. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994; 81: 171-6.
76. Sanchez FO, Rodriguez JI, Agudelo G, Garcia LF. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect Immun 1994; 62: 5673-8.
77. Lienhardt C, Azzurri A, Amedei A et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002; 32: 1605-13.
78. Elliott AM, Hodsdon WS, Kyosiimire J et al. Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Trans R Soc Trop Med Hyg 2004; 98: 660-70.
79. Rook GA, Hernandez-Pando R, Dheda K, Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004; 25: 483-8.
80. Zhang M, Gately MK, Wang E et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93: 1733-9.
81. Lin Y, Zhang M, Hofman FM, Gong J, Barnes PF. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 1996; 64: 1351-6.
82. Burgess LJ, Reuter H, Carstens ME, Taljaard JJ, Doubell AF. Cytokine production in patients with tuberculous pericarditis. Int J Tuberc Lung Dis 2002; 6: 439-46.
83. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-73.
84. Van den Bergh R, Vanham G, Raes G, De Baetselier P, Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis 2006; 6: 2-3. author reply: 4-5.
85. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42: 1639-46.
86. Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18: 384-8.
87. Kivihya-Ndugga LE, van Cleeff MR, Githui WA et al. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis 2003; 7: 1163-71.
88. Kocagoz T, O'Brien R, Perkins M. A new colorimetric culture system for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1512.
89. Rathman G, Sillah J, Hill PC et al. Clinical and radiological presentation of 340 adults with smear-positive tuberculosis in The Gambia. Int J Tuberc Lung Dis 2003; 7: 942-7.
90. van Cleeff MR, Kivihya-Ndugga LE, Meme H, Odhiambo JA, Klatser PR. The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis 2005; 5: 111.
91. Elliott AM, Namaambo K, Allen BW et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis 1993; 74: 191-4.
92. Perlman DC, el-Sadr WM, Nelson ET et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997; 25: 242-6.
93. World Health Organization. Preventive therapy against tuberculosis in people living with HIV. Policy statement. Wkly Epidemiol Rec 1999; 74: 385-98.
94. Mosimaneotsile B, Talbot E, Moeti TL et al. Value of chest radiography ina tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 2003; 362: 1551-2.
95. Whalen CC. Diagnosis of latent tuberculosis infection: measure for measure. JAMA 2005; 293: 2785-7.
96. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-104.
97. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804-9.
98. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999; 3: 962-75.
99. Nakamura RM, Velmonte MA, Kawajiri K et al. MPB64 mycobacterial antigen: a new skin-test reagent through patch method for rapid diagnosis of active tuberculosis. Int J Tuberc Lung Dis 1998; 2: 541-6.
100. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 2006; 6: 423-32.
101. Barnes PF. Diagnosing latent tuberculosis infection: turning glitter to gold. Am J Respir Crit Care Med 2004; 170: 5-6.
102. Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-7.
103. Ferrara G, Losi M, D'Amico R et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-34.
104. Pai M. The accuracy and reliability of nucleic acid amplification tests in the diagnosis of tuberculosis. Natl Med J India 2004; 17: 233-6.
105. Chapman AL, Munkanta M, Wilkinson KA et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-93.
106. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004; 364: 2196-203.
107. Harboe M, Wiker HG. The 38-kDa protein of Mycobacterium tuberculosis: a review. J Infect Dis 1992; 166: 874-84.
108. Silva VM, Kanaujia G, Gennaro ML, Menzies D. Factors associated with humoral response to ESAT-6, 38 kDa and 14 kDa in patients with a spectrum of tuberculosis. Int J Tuberc Lung Dis 2003; 7: 478-84.
109. Richeldi L, Ewer K, Losi M et al.. Early diagnosis of subclinical multidrug-resistant tuberculosis. Ann Intern Med 2004; 140: 709-13.
110. Ravn P, Munk ME, Andersen AB et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 2005; 12: 491-6.
111. Weldingh K, Rosenkrands I, Okkels LM, Doherty TM, Andersen P. Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. J Clin Microbiol 2005; 43: 57-65.
112. Jacobs WR Jr, Barletta RG, Udani R et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260: 819-22.
113. Ellner J. The host immune response to tuberculosis: implications for tuberculosis control. J Infect Dis 1997; 176: 1351-9.
114. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-3.
115. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006; 74: 4634-43.
116. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998; 2: 200-7.
117. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-45.
118. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing. Geneva World Health Organization: WHO/HTM/TB/2005. 349.
119. Behr MA. BCG - different strains, different vaccines? Lancet Infect Dis 2002; 2: 86-92.
120. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 94: 553-68.
121. Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 2005; 73: 2190-6.
122. Haile M, Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 2005; 18: 211-5.
123. Bolger T, O'Connell M, Menon A, Butler K. Complications associated with the bacille Calmette-Guerin vaccination in Ireland. Arch Dis Child 2006; 91: 594-7.
124. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
125. Doherty TM, Andersen P. Tuberculosis vaccine development. Curr Opin Pulm Med 2002; 8: 183-7.
126. Martin C. Tuberculosis vaccines: past, present and future. Curr Opin Pulm Med 2006; 12: 186-91.
127. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10: 1240-4.
128. Li JM, Zhu DY. Therapeutic DNA vaccines against tuberculosis: a promising but arduous task. Chin Med J (Engl) 2006; 119: 1103-7.
129. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3: 656-62.
130. Langermans JA, Doherty TM, Vervenne RA et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005; 23: 2740-50.
131. Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005; 7: 947-54.
132. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 2006; 24: 1593-600.
133. Pym AS, Brodin P, Majlessi L et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9: 533-9.
134. Irwin SM, Izzo AA, Dow SW et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 2005; 73: 5809-16.
135. Dietrich J, Weldingh K, Andersen P. Prospects for a novel vaccine against tuberculosis. Vet Microbiol 2006; 112: 163-9.
136. Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005; 85: 29-38.
137. Campos JM, Simonetti JP, Pone MV, Carvalho LA, Pereira AC, Garrido JR. Disseminated Bacillus Calmette-Guerin infection in HIV-infected children: case report and review. Pediatr AIDS HIV Infect 1996; 7: 429-32.
138. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006; 4: 469-76.
139. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3(10 Suppl. 2): S231-79.
140. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-51.
141. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
142. Myers JP. New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 2005; 18: 133-40.
143. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Recommendations for a Public Health Approach. Geneva: World Health Organization, 2006.
144. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293: 2776-84.
145. Mitchison DA. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167: 1298-9.
146. Mwinga A, Nunn A, Ngwira B et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360: 1050-5.
147. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-51.
148. Lalvani A, Nagvenkar P, Udwadia Z et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001; 183: 469-77.
149. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26: 28-106.
150. Whalen CC, Johnson JL, Okwera A et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-8.
151. Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. Cochrane Database Syst Rev 2000; CD000171.
152. Grant AD, Charalambous S, Fielding KL et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293: 2719-25.
153. Hawken MP, Muhindi DW. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Int J Tuberc Lung Dis 1999; 3: 646-50.
154. Aisu T, Raviglione MC, van Praag E et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 1995; 9: 267-73.
155. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72.
156. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-4.
157. Mwinga A, Hosp M, Godfrey-Faussett P et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-57.
158. The Global Alliance for TB Drug Development. Executive Summary for the Economics of TB Drug Development. Pekar N (ed.). Washington DC: The Global Aliance for TB Drug Development 2001.
159. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs 2000; 59: 7-16.
160. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-8.
161. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis 1985; 131: 348-51.
162. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362: 887-99.
163. Drobniewski F, Balabanova Y, Coker R. Clinical features, diagnosis, and management of multiple drug-resistant tuberculosis since 2002. Curr Opin Pulm Med 2004; 10: 211-7.
164. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva World Health Organization: WHO/HTM/TB/2006. 361.
165. Suarez PG, Floyd K, Portocarrero J et al. Feasibility and costeffectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-9.
166. Castro K. Extensively Drug-Resistant TB (XDR TB) Summary Report. Paris: 37th Union World Conference on Lung Health, 2006.